CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-13). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 241 · Search date 2026-07-13 · Methodology v0.6

Apigenin,
does it really help with Sleep quality and tension relief?

30-Second Summary
?
Evidence Grade ? · Safety unknown
Chamomile research cannot be transferred directly to claims that isolated apigenin improves sleep or relieves tension
What the
research shows
No human efficacy trial was identified that administered isolated apigenin orally as a supplement to test sleep quality or tension relief. Results from chamomile extracts or chamomile tea concern multiconstituent products and cannot be attributed to isolated apigenin; the grade remains ?.
What the
ads claim
Marketed products present isolated apigenin at 25-50 mg as a 'sleep aid' or 'tension relief' ingredient. Human studies generally evaluated chamomile extract and do not directly support efficacy of isolated apigenin capsules at those doses.
*

Useful facts when choosing a product

  • Chamomile extract contains multiple flavonoids and volatile-oil constituents in addition to apigenin.
  • Analytical testing found about 3.9 mg of apigenin in each 90 mg of chamomile extract used in the insomnia RCT.
  • Long-term human safety and interaction data for isolated apigenin supplements are limited.
Gap Measurement · Verdict 241 · ?
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Zick 2011 gave 34 patients with chronic primary insomnia 270 mg of apigenin-containing chamomile extract twice daily for 28 days, but found no difference from placebo in the main sleep-diary measures, including total sleep time, sleep efficiency, sleep latency, wake after sleep onset, awakenings, and sleep quality. The Amsterdam 2009 chamomile-extract RCT reported a signal for reduced HAM-A scores in mild-to-moderate generalized anxiety disorder, but this was an effect of the whole extract. A 2024 review of apigenin and sleep likewise concluded that human clinical data are limited to apigenin-containing chamomile studies and cannot distinguish apigenin's individual contribution.

02

Why this is classified as ?

Relevant mechanistic and animal data and human chamomile trials exist, but no efficacy trial of isolated apigenin addresses the stated effects. To avoid ingredient extrapolation, the rating is ? and the score is null.

Counterpoint. Anxiety signals from whole chamomile extract remain hypothesis-forming evidence. This assessment is limited to claims for isolated apigenin supplements, not chamomile.

Rejudgment record. Reassessment (cross-check reflected) — No human efficacy trial has tested isolated apigenin alone, and results from chamomile extracts or tea concern multiconstituent products and cannot be attributed to isolated apigenin; the grade remains ?

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Zick SM et al. 2011Randomized double-blind placebo-controlled pilot trial34Supported by the U.S. NCCAMTotal sleep time, efficiency, latency, awakenings, and sleep qualityApigenin-containing chamomile extract did not differ significantly from placebo on any primary sleep-diary endpoint.Key
Amsterdam JD et al. 2009Randomized double-blind placebo-controlled trial57Supported by the U.S. NIHHAM-A anxiety symptomsChamomile extract showed an anxiety-reduction signal, but this was a multi-constituent extract result and not an effect of apigenin alone.Limited extrapolation
Kramer DJ, Johnson AA. 2024Narrative reviewSupported by Tally Health with affiliated authorsEvidence related to sleep and agingConcluded that human sleep data are limited to chamomile studies and cannot establish the contribution of apigenin alone.Supportive
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-13).

Zick SM, Wright BD, Sen A, Arnedt JT. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complement Altern Med. 2011;11:78. PMID: 21939549. DOI: 10.1186/1472-6882-11-78.
checked
Amsterdam JD, Li Y, Soeller I, Rockwell K, Mao JJ, Shults J. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(4):378-382. PMID: 19593179. DOI: 10.1097/JCP.0b013e3181ac935c.
checked
Kramer DJ, Johnson AA. Apigenin: a natural molecule at the intersection of sleep and aging. Front Nutr. 2024;11:1359176. PMID: 38476603. DOI: 10.3389/fnut.2024.1359176.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-13 · Corrections: none

Cite this verdict

Apigenin x sleep quality and tension relief Evidence Grade ? card
[Chamgap] Apigenin x sleep quality and tension relief — Evidence Grade ?. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/sleep/apigenin-sleep-tension/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.